Hearing loss prevalence and associated factors in chronic kidney disease patients under conservative treatment

• Autor(a) principal: Assis Espindula Mota, Monik
• Data de Publicação: 2020
• Outros Autores: Otávio do Amaral Corrêa, Jose, Erothildes Ferreira, Renato, Rodrigues Mendes Moraes , Matheus, Parisi Marlière , Bruno, Antonio Basile Colugnati, Fernando
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: HU Revista (Online)
• Texto Completo: https://periodicos.ufjf.br/index.php/hurevista/article/view/28887
• topic: Chronic Kidney Disease; Hearing Loss; Prevalence; Inflammatory markers; Cytokines; Doença Renal Crônica; Perda Auditiva Neurossensorial; Prevalência; Marcadores Inflamatórios; Citocinas

Introduction: Hearing loss is an increasingly condition seen in the population. It is found with greater frequency in some specific groups such as elderly people, people with systemic arterial hypertension and diabetes mellitus. Evidence suggests increased prevalence of hearing loss in patients with chronic kidney disease (CKD), however studies in the brazilian population with CKD are scarce. Objective: To evaluate the prevalence of hearing loss in a population of patients with chronic kidney disease non dyalitic and associated factors. Material and methods: We used a convenience sample of patients with CKD (n = 159), aged 18 to 65 years in multidisciplinary healthcare service. The auditory acuity was assessed by pure-tone audiometry threshold and by the questionnaire WHO Ear and Hearing Disorders Survey Protocol for a Population-Based Survey of Prevalence and Causes of Deafness and Hearing Impairment and other Ear Diseases translated and validated into Portuguese. We collected demographic and clinical data, also carried out otoscopy, and dosage of biochemical markers and inflammatory cytokines TNF-α, IFN-γ, IL-1β, IL-6, IL-10, IL-17. Results: In the analyses we checked the prevalence of 25,16% of hearing loss among the participants. In our study we did not find any association between the progression of the stages of CKD and the increase of the prevalence of hearing impairment, nor with its severity. The blood markers analyses, isolated or in association to CKD stages, were not able to establish a relation between the progression of stage of chronic kidney disease and hearing loss. Conclusions: The prevalence of hearing loss in this study is 25,16%. It is recommended that strategies be implemented for the prevention and reversal of this situation in this target group.